Global Atrial Fibrillation Market by Procedure (Pharmacological Drugs, Anti-Arrhythmic, Anti-Coagulant, Non-Pharmacological, Radiofrequency, Hifu, Cryoablation, Microwave, Laser, Catheter Ablation, Maze Surger) Expected

The global market for atrial fibrillation procedures and products is expected to reach USD 16.17 billion by 2020 growing at a CAGR of 13.2%, according to a new study by Grand View Research, Inc. Growing incidences of atrial fibrillation, strokes and brain damage due to blood clots coupled with a growing global base of geriatric population is expected to be a key driver for this market. Some of the other drivers of this market include the introduction of technological advancements in the fields of radiofrequency and microwave catheter ablation, growing demand for minimally invasive procedures and increasing prevalence of disease causing lifestyle habits such as smoking and excessive alcohol consumption. Pharmacological products for Atrial Fibrillation dominated the overall market in terms of revenue in 2013 at over 55.0%. Relatively low prices associated with these products and the use of anti-coagulants as an add-on therapy to non-pharmacological procedures, are some of the drivers of this segment.

The report “Atrial Fibrillation Market Analysis By Procedure (Pharmacological Drugs, Anti-arrhythmic, Anti-coagulant, Non-Pharmacological Treatments, Radiofrequency, HIFU, Cryoablation, Microwave, Laser, Catheter Ablation, Maze Surgery, Electric Cardioversion) And Segment Forecasts To 2020,” is available now toGrand View Researchcustomers and can also be purchased directly at http://www.grandviewresearch.com/industry-analysis/atrial-fibrillation-treatment-industry

Further key findings from the study suggest:

• Regionally, North America occupied the largest share of the market, accounting for over 42% of the global revenue in 2013. Its large share is majorly attributed by the presence of high market penetration rates of non-pharmacological procedures and sophisticated reimbursement frameworks.

• Asia Pacific is expected to register the highest CAGR of 15.3% during the forecast period. Growing demand for non-pharmacological treatments on account of constantly...